AIDS-defining illnesses: a comparison between before and after commencement of highly active antiretroviral therapy (HAART)

Attempts to address the significant impact of HAART on medical variables on the Malaysian HIV/AIDS population have yet to be evaluated. This study aims to analyze the proportions of AIDS-defining illnesses (ADIs) before and after HAART. A retrospective study was carried out on 128 new cases of HIV i...

Full description

Saved in:
Bibliographic Details
Main Authors: Lian, Y.L.A., Heng, B.S.L., Nissapatorn, V., Lee, C.
Format: Article
Published: 2007
Subjects:
Online Access:http://eprints.um.edu.my/4171/
http://www.ncbi.nlm.nih.gov/pubmed/17896968
Tags: Add Tag
No Tags, Be the first to tag this record!
id my.um.eprints.4171
record_format eprints
spelling my.um.eprints.41712012-12-12T04:13:23Z http://eprints.um.edu.my/4171/ AIDS-defining illnesses: a comparison between before and after commencement of highly active antiretroviral therapy (HAART) Lian, Y.L.A. Heng, B.S.L. Nissapatorn, V. Lee, C. R Medicine Attempts to address the significant impact of HAART on medical variables on the Malaysian HIV/AIDS population have yet to be evaluated. This study aims to analyze the proportions of AIDS-defining illnesses (ADIs) before and after HAART. A retrospective study was carried out on 128 new cases of HIV infected patients who first commenced HAART in 2004 at the national HIV reference center. Before commencement of HAART, 76 clinical episodes of ADIs were recorded in 52 patients. Most common being pulmonary Mycobacterium tuberculosis (28.9), PCP (27.6) and disseminated and extrapulmonary Mycobacterium tuberculosis (11.8). During HAART, 8 clinical episodes of ADIs were documented in 7 patients with a median time of onset of 10 weeks after initiation of HAART (range, 4-36 weeks). The median CD4 count at the time of the commencement of HAART for these patients was 11 cells/mm(3). ADIs reported include PCP (2 episodes), disseminated and extrapulmonary Mycobacterium tuberculosis (2 episodes), extrapulmonary cryptococcosis (1 episode), esophageal candidiasis (1 episode), recurrent pneumonia (1 episode) and disseminated or extrapulmonary histoplasmosis (1 episode). Three (37.5) of these occurred despite a reduction of viral load by at least 2 log(10) and an increased in the CD4 cell count. In conclusion, ADIs can still present after the initiation of successful HAART especially in those with CD4 counts below 100 cells/mm(3). In Malaysia, ADIs are the major causes of HIV/AIDS associated morbidity and mortality, thus increased awareness on the management of these illnesses is warranted especially in the months following HAART. 2007 Article PeerReviewed Lian, Y.L.A. and Heng, B.S.L. and Nissapatorn, V. and Lee, C. (2007) AIDS-defining illnesses: a comparison between before and after commencement of highly active antiretroviral therapy (HAART). Current Hiv Research, 5 (5). pp. 484-489. ISSN 1570-162X http://www.ncbi.nlm.nih.gov/pubmed/17896968 17896968
institution Universiti Malaya
building UM Library
collection Institutional Repository
continent Asia
country Malaysia
content_provider Universiti Malaya
content_source UM Research Repository
url_provider http://eprints.um.edu.my/
topic R Medicine
spellingShingle R Medicine
Lian, Y.L.A.
Heng, B.S.L.
Nissapatorn, V.
Lee, C.
AIDS-defining illnesses: a comparison between before and after commencement of highly active antiretroviral therapy (HAART)
description Attempts to address the significant impact of HAART on medical variables on the Malaysian HIV/AIDS population have yet to be evaluated. This study aims to analyze the proportions of AIDS-defining illnesses (ADIs) before and after HAART. A retrospective study was carried out on 128 new cases of HIV infected patients who first commenced HAART in 2004 at the national HIV reference center. Before commencement of HAART, 76 clinical episodes of ADIs were recorded in 52 patients. Most common being pulmonary Mycobacterium tuberculosis (28.9), PCP (27.6) and disseminated and extrapulmonary Mycobacterium tuberculosis (11.8). During HAART, 8 clinical episodes of ADIs were documented in 7 patients with a median time of onset of 10 weeks after initiation of HAART (range, 4-36 weeks). The median CD4 count at the time of the commencement of HAART for these patients was 11 cells/mm(3). ADIs reported include PCP (2 episodes), disseminated and extrapulmonary Mycobacterium tuberculosis (2 episodes), extrapulmonary cryptococcosis (1 episode), esophageal candidiasis (1 episode), recurrent pneumonia (1 episode) and disseminated or extrapulmonary histoplasmosis (1 episode). Three (37.5) of these occurred despite a reduction of viral load by at least 2 log(10) and an increased in the CD4 cell count. In conclusion, ADIs can still present after the initiation of successful HAART especially in those with CD4 counts below 100 cells/mm(3). In Malaysia, ADIs are the major causes of HIV/AIDS associated morbidity and mortality, thus increased awareness on the management of these illnesses is warranted especially in the months following HAART.
format Article
author Lian, Y.L.A.
Heng, B.S.L.
Nissapatorn, V.
Lee, C.
author_facet Lian, Y.L.A.
Heng, B.S.L.
Nissapatorn, V.
Lee, C.
author_sort Lian, Y.L.A.
title AIDS-defining illnesses: a comparison between before and after commencement of highly active antiretroviral therapy (HAART)
title_short AIDS-defining illnesses: a comparison between before and after commencement of highly active antiretroviral therapy (HAART)
title_full AIDS-defining illnesses: a comparison between before and after commencement of highly active antiretroviral therapy (HAART)
title_fullStr AIDS-defining illnesses: a comparison between before and after commencement of highly active antiretroviral therapy (HAART)
title_full_unstemmed AIDS-defining illnesses: a comparison between before and after commencement of highly active antiretroviral therapy (HAART)
title_sort aids-defining illnesses: a comparison between before and after commencement of highly active antiretroviral therapy (haart)
publishDate 2007
url http://eprints.um.edu.my/4171/
http://www.ncbi.nlm.nih.gov/pubmed/17896968
_version_ 1643687278968569856
score 13.160551